Naproxen vs. Ibuprofen for Personal Injury Pain: Which NSAID Is Better?

James Wong — Founder & Pharmacist, LienScripts | February 11, 2026 | 7 min read

A clinical comparison of the two most common NSAIDs in personal injury settings. Understand half-life, GI risk, cardiovascular profiles, Rx-strength dosing, and how pharmacy liens cover both.

NSAIDs in Personal Injury Pain Management: Why the Choice Matters

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications for personal injury patients. Two NSAIDs dominate outpatient PI prescribing: naproxen and ibuprofen. Both inhibit cyclooxygenase (COX) enzymes to reduce pain and inflammation, both are available at prescription strength, and both are covered under pharmacy lien programs. But they differ meaningfully in pharmacokinetics, dosing frequency, gastrointestinal risk, cardiovascular profile, and clinical utility in the PI setting.

This article compares naproxen and ibuprofen to help patients, attorneys, and treating physicians understand which NSAID is selected, when, and why — and how pharmacy liens support access to prescription-strength NSAID therapy throughout a personal injury case.

Mechanism of Action: COX-1 and COX-2 Inhibition

Both naproxen and ibuprofen are non-selective NSAIDs that inhibit both COX-1 and COX-2 enzymes. COX-2 inhibition drives their anti-inflammatory and analgesic effects by reducing prostaglandin synthesis at sites of injury and inflammation. COX-1 inhibition is responsible for many of the GI side effects associated with NSAIDs, as COX-1 helps maintain the protective gastric mucosa.

Neither ibuprofen nor naproxen has meaningful selectivity for COX-2 over COX-1 at typical therapeutic doses. This contrasts with COX-2 selective agents (celecoxib, no longer widely available), which were developed specifically to reduce GI risk. The non-selective profile of both medications means they carry comparable GI risks, though duration of action and other factors influence which drug is better tolerated in a given patient.

[!KEY] Ibuprofen and naproxen are both non-selective COX inhibitors, but their half-lives differ dramatically — this difference in duration of action is the key clinical factor driving dosing frequency and patient adherence in PI cases.

Half-Life and Dosing Frequency

The most clinically significant pharmacokinetic difference between naproxen and ibuprofen is half-life.

Naproxen has a half-life of approximately 12 to 17 hours. This long half-life supports twice-daily (BID) dosing, which simplifies adherence for injury patients managing complex treatment regimens. Prescription-strength naproxen is typically dosed at 375-500 mg BID, with a maximum daily dose of 1,500 mg for prescription formulations.

Ibuprofen has a much shorter half-life of approximately 2 hours, requiring three-to-four times daily (TID-QID) dosing to maintain therapeutic anti-inflammatory concentrations. Prescription-strength ibuprofen is typically dosed at 400-800 mg TID-QID, with a maximum daily dose of 3,200 mg for prescription formulations.

For personal injury patients already managing multiple medications, appointments, and legal processes, the convenience of twice-daily naproxen versus three-to-four times daily ibuprofen is a meaningful practical difference.

[!SOURCE] Naproxen half-life and dosing: prescribing information for Naprosyn (naproxen), FDA NDA 018164. Ibuprofen half-life and dosing: prescribing information for Motrin (ibuprofen), FDA NDA 017463.

Gastrointestinal Risk Profile

Gastrointestinal adverse effects — ulceration, bleeding, and perforation — are the primary safety concern with non-selective NSAIDs. Both naproxen and ibuprofen can cause GI injury, but evidence suggests differences in relative risk at therapeutic doses.

Ibuprofen at standard doses is associated with a relatively low GI risk profile compared to naproxen and other NSAIDs. However, at higher prescription doses (800 mg TID-QID), GI risk increases substantially. The frequent dosing requirement means more opportunities for GI exposure.

Naproxen is generally associated with a somewhat higher GI risk than ibuprofen when used at full anti-inflammatory doses, though meta-analyses have shown variable results depending on dose and patient population.

For both agents, GI risk is significantly reduced by co-prescribing a proton pump inhibitor (PPI) such as omeprazole or pantoprazole. In PI practice, it is common for physicians to prescribe an NSAID together with a PPI — particularly for patients who require sustained NSAID therapy. Both the NSAID and the PPI can be covered under a pharmacy lien arrangement.

Renal Considerations

All NSAIDs carry the potential for renal adverse effects through inhibition of prostaglandin-mediated renal blood flow regulation. This risk is elevated in elderly patients, those with pre-existing kidney disease, and in settings of dehydration or volume depletion (relevant in acute injury or post-surgical patients).

For most otherwise healthy PI patients, short-term NSAID use at appropriate doses poses minimal renal risk. Clinicians managing patients with renal comorbidities, or those requiring prolonged NSAID therapy, monitor renal function and may limit duration of use or use the lowest effective dose.

Cardiovascular Risk

All non-selective NSAIDs carry a class-wide FDA warning for cardiovascular risk — increased risk of serious cardiovascular events including myocardial infarction and stroke, especially with prolonged use. However, within the NSAID class, evidence suggests naproxen may have a comparatively more favorable cardiovascular profile.

The proposed mechanism relates to platelet effects. Naproxen reversibly inhibits platelet COX-1 in a manner that partially mimics aspirin, providing some antiplatelet effect. This may attenuate the prothrombotic risk associated with COX-2 inhibition. Ibuprofen, by contrast, can competitively interfere with low-dose aspirin antiplatelet action — a relevant concern for PI patients with cardiovascular comorbidities who are on aspirin therapy.

For most younger, otherwise healthy PI patients, the cardiovascular risk difference between naproxen and ibuprofen at short-to-medium durations is modest. But for patients with cardiac history or who are on aspirin, naproxen is generally preferred.

Prescription-Strength vs. OTC Dosing in PI Settings

Both naproxen and ibuprofen are available over the counter, but the doses available OTC are lower than full prescription anti-inflammatory doses. OTC naproxen sodium (Aleve) is typically 220 mg per dose; prescription naproxen is 375-500 mg per dose. OTC ibuprofen (Advil, Motrin IB) is typically 200-400 mg per dose; prescription ibuprofen reaches 600-800 mg per dose.

For anti-inflammatory management of soft tissue injuries, herniated discs, post-surgical inflammation, or other PI conditions, prescription-strength NSAIDs are often necessary to achieve therapeutic concentrations. A pharmacy lien covers prescription-strength NSAIDs dispensed by a participating pharmacy.

Role of the PPI: Gastroprotection in PI Patients

When either naproxen or ibuprofen is prescribed for more than short-term use in PI cases, co-prescribing a proton pump inhibitor is standard of care for patients with GI risk factors. Risk factors include:

• Age over 65
• History of peptic ulcer disease or GI bleeding
• Concurrent corticosteroid use
• Concurrent anticoagulant use
• Higher NSAID doses

Common PPIs used alongside NSAIDs in PI include omeprazole (generic Prilosec), pantoprazole (generic Protonix), and esomeprazole (generic Nexium). When prescribed as part of injury-related care, PPIs can also be included in a pharmacy lien arrangement alongside the NSAID.

[!KEY] Co-prescribing a PPI with an NSAID significantly reduces GI ulceration risk. In PI cases requiring prolonged NSAID therapy — such as post-surgical inflammation or chronic soft tissue injuries — gastroprotection is standard of care and pharmacy liens cover both medications.

When PI Physicians Switch from One NSAID to the Other

PI physicians may switch between naproxen and ibuprofen based on several factors:

• Tolerability: A patient who experiences GI upset or headache with one NSAID may tolerate the other better.
• Adherence: A patient struggling to take medications four times daily may benefit from switching to twice-daily naproxen.
• Cardiovascular considerations: A patient with cardiac risk factors or on aspirin may be switched to naproxen for a more favorable cardiovascular profile.
• Drug interactions: Ibuprofen can interfere with the antiplatelet action of low-dose aspirin; naproxen does not have this interaction at the same magnitude.
• Renal function changes: Monitoring labs may prompt dose reduction or a switch if early renal signals appear.

Pharmacy Liens Cover Prescription-Strength NSAIDs

Personal injury patients prescribed naproxen or ibuprofen at prescription strength can access these medications through a pharmacy lien program at no upfront cost. The lien covers the dispensed prescription and is satisfied from settlement proceeds at case resolution.

Both the NSAID and any co-prescribed gastroprotective PPI are eligible for pharmacy lien coverage when prescribed as part of injury-related care. Documentation in the medical record linking the NSAID prescription to the injury diagnosis is essential for a valid lien claim.

Related Resources

• What Is a Pharmacy Lien?
• Omeprazole and NSAID Gastroprotection in Personal Injury
• Herniated Disc Medications and Pharmacy Lien
• Soft Tissue Injury Medications
• Pain Management After a Car Accident